Technical Analysis for AVDL - Avadel Pharmaceuticals plc

Grade Last Price % Change Price Change
F 14.12 0.43% 0.06
AVDL closed up 0.43 percent on Monday, July 1, 2024, on 1.4 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 200 DMA Bearish 0.43%
Slingshot Bearish Bearish Swing Setup 0.43%
Stochastic Buy Signal Bullish 0.43%
Volume Surge Other 0.43%
Lower Bollinger Band Walk Weakness 0.43%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 6 hours ago
Possible Inside Day about 6 hours ago
Down 2 % about 8 hours ago
60 Minute Opening Range Breakdown about 8 hours ago
Fell Below Lower Bollinger Band about 8 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avadel Pharmaceuticals plc Description

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Drugs Organ Systems Surgery Psychoactive Drugs Chloride Reversal Amines Anesthesia Sleep Disorders Narcolepsy Choline Phenols Cataplexy Cholinesterase Phenylephrine Muscle Relaxants

Is AVDL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.09
52 Week Low 9.5
Average Volume 1,394,689
200-Day Moving Average 14.12
50-Day Moving Average 16.12
20-Day Moving Average 15.04
10-Day Moving Average 14.70
Average True Range 0.72
RSI (14) 31.97
ADX 23.65
+DI 9.07
-DI 23.47
Chandelier Exit (Long, 3 ATRs) 13.93
Chandelier Exit (Short, 3 ATRs) 15.59
Upper Bollinger Bands 16.18
Lower Bollinger Band 13.90
Percent B (%b) 0.09
BandWidth 15.11
MACD Line -0.49
MACD Signal Line -0.40
MACD Histogram -0.0864
Fundamentals Value
Market Cap 1.27 Billion
Num Shares 89.8 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -6.57
Price-to-Sales 157.87
Price-to-Book 11.76
PEG Ratio 0.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.93
Resistance 3 (R3) 14.89 14.58 14.80
Resistance 2 (R2) 14.58 14.37 14.60 14.75
Resistance 1 (R1) 14.35 14.24 14.46 14.39 14.71
Pivot Point 14.03 14.03 14.09 14.05 14.03
Support 1 (S1) 13.81 13.83 13.92 13.85 13.53
Support 2 (S2) 13.49 13.70 13.51 13.49
Support 3 (S3) 13.26 13.49 13.44
Support 4 (S4) 13.31